Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:24 AM
Study NCT ID:
NCT00320710
Status:
COMPLETED
Last Update Posted:
2014-08-22
First Post:
2006-04-28
Brief Title:
Continued Efficacy and Safety of Zoledronic Acid q 4 Wks vs q 12 Wks in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
A Prospective Randomized Double-blind Stratified Multi-center 2-arm Trial of the Continued Efficacy and Safety of Zoledronic Acid Every 4 Weeks vs Every 12 Weeks in in the 2nd Year of Treatment in Patients With Documented Bone Metastases From Breast Cancer
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen Looking at the continued effectiveness and safety of giving zoledronic acid every 4 weeks versus every 12 weeks given over 1 year This study is prospective double-blind stratified multi-center and two-arm
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None